Sky Century Investment (SKYI) Cash from Financing Activities (2012 - 2026)
Sky Century Investment (SKYI) posted quarterly Cash from Financing Activities of $86222.0 for Q2 2026, up 729.7% year-over-year from $10392.0 in Q2 2025, and up 12043.94% quarter-over-quarter from $710.0 in Q1 2026.
Sky Century Investment (SKYI) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has reported Cash from Financing Activities for 6 consecutive years, with $86222.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 729.7% year-over-year to $86222.0; the TTM figure through May 2026 stood at $111132.0 (up 89.5% YoY), while the FY2025 annual figure was $46136.0, up 59.08% from the prior year.
- Cash from Financing Activities advanced to $86222.0 in Q2 2026 per SKYI's latest filing, from $710.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $86222.0 in Q2 2026 and bottomed at $710.0 in Q1 2026.
- Historically, Cash from Financing Activities has averaged $21958.9 across 3 years, with a median of $11668.5 in 2024.
- On a YoY basis, Cash from Financing Activities climbed as much as 729.7% in 2026 and fell as far as 97.15% in 2026.
- Sky Century Investment's Cash from Financing Activities stood at $10827.0 in 2024, then jumped by 123.52% to $24200.0 in 2025, then soared by 256.29% to $86222.0 in 2026.
- Business Quant data shows SKYI's Cash from Financing Activities at $86222.0 in Q2 2026, $710.0 in Q1 2026, and $24200.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Sky Century Investment | 393,547.71 | 393,283.71 | 26,045.00 | 86,222.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 86,222.00 |
| May 31, 2026 | 86,222.00 |
| Feb 28, 2026 | 710.00 |
| Feb 28, 2026 | 710.00 |
| Nov 30, 2025 | 24,200.00 |
| Nov 30, 2025 | 24,200.00 |
| May 31, 2025 | 10,392.00 |
| May 31, 2025 | 10,392.00 |
| Feb 28, 2025 | 24,917.00 |
| Feb 28, 2025 | 24,917.00 |
| Nov 30, 2024 | 10,827.00 |
| Nov 30, 2024 | 10,827.00 |
| Aug 31, 2024 | 12,510.00 |
| Aug 31, 2024 | 12,510.00 |
| May 31, 2024 | 5,893.00 |
| May 31, 2024 | 5,893.00 |
| May 31, 2014 | 1,130.00 |
| May 31, 2014 | 1,130.00 |
| Nov 30, 2013 | 10,350.00 |
| Nov 30, 2013 | 10,350.00 |